Amicus Therapeutics Statistics

Total Valuation

LON:0HF9 has a market cap or net worth of GBP 1.31 billion. The enterprise value is 1.45 billion.

Market Cap	1.31B
Enterprise Value	1.45B

Important Dates

The next estimated earnings date is Wednesday, August 6, 2025.

Earnings Date	Aug 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	307.93M
Shares Outstanding	n/a
Shares Change (YoY)	+2.52%
Shares Change (QoQ)	+0.50%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	263.93M

Valuation Ratios

PE Ratio	n/a
Forward PE	14.16
PS Ratio	3.12
PB Ratio	8.74
P/TBV Ratio	n/a
P/FCF Ratio	1,052.31
P/OCF Ratio	475.05
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 30.47, with an EV/FCF ratio of 1,167.35.

EV / Earnings	-63.91
EV / Sales	3.60
EV / EBITDA	30.47
EV / EBIT	40.96
EV / FCF	1,167.35

Financial Position

The company has a current ratio of 3.34, with a Debt / Equity ratio of 2.29.

Current Ratio	3.34
Quick Ratio	2.22
Debt / Equity	2.29
Debt / EBITDA	6.90
Debt / FCF	275.79
Interest Coverage	0.98

Financial Efficiency

Return on equity (ROE) is -18.12% and return on invested capital (ROIC) is 4.93%.

Return on Equity (ROE)	-18.12%
Return on Assets (ROA)	3.95%
Return on Invested Capital (ROIC)	4.93%
Return on Capital Employed (ROCE)	7.50%
Revenue Per Employee	842,456
Profits Per Employee	-45,560
Employee Count	499
Asset Turnover	0.72
Inventory Turnover	0.53

Taxes

In the past 12 months, LON:0HF9 has paid 20.24 million in taxes.

Income Tax	20.24M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -41.53% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-41.53%
50-Day Moving Average	6.41
200-Day Moving Average	9.08
Relative Strength Index (RSI)	33.70
Average Volume (20 Days)	918

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	4.28

Income Statement

In the last 12 months, LON:0HF9 had revenue of GBP 420.39 million and -22.73 million in losses. Loss per share was -0.07.

Revenue	420.39M
Gross Profit	380.85M
Operating Income	36.99M
Pretax Income	-2.49M
Net Income	-22.73M
EBITDA	43.36M
EBIT	36.99M
Loss Per Share	-0.07

Full Income Statement

Balance Sheet

The company has 193.94 million in cash and 343.24 million in debt, giving a net cash position of -149.30 million.

Cash & Cash Equivalents	193.94M
Total Debt	343.24M
Net Cash	-149.30M
Net Cash Per Share	n/a
Equity (Book Value)	149.81M
Book Value Per Share	0.49
Working Capital	277.02M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.76 million and capital expenditures -1.51 million, giving a free cash flow of 1.24 million.

Operating Cash Flow	2.76M
Capital Expenditures	-1.51M
Free Cash Flow	1.24M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 90.60%, with operating and profit margins of 8.80% and -5.41%.

Gross Margin	90.60%
Operating Margin	8.80%
Pretax Margin	-0.59%
Profit Margin	-5.41%
EBITDA Margin	10.31%
EBIT Margin	8.80%
FCF Margin	0.30%

Dividends & Yields

LON:0HF9 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.52%
Shareholder Yield	n/a
Earnings Yield	-1.74%
FCF Yield	0.10%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0HF9 has an Altman Z-Score of -0.4 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.4
Piotroski F-Score	6